(Q37751910)

English

The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials

scientific article published on 23 April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1 reference

Europe PubMed Central

The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

systematic review

1 reference

based on heuristic

inferred from title

Ursula Gundert-Remy

4

object named as

Ursula Gundert-Remy

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

author name string

Gisela Schott

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Henry Pachl

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Ulrich Limbach

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Wolf-Dieter Ludwig

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Klaus Lieb

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

publication date

23 April 2010

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Deutsches Ärzteblatt international

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

107

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

16

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

279-285

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Evolution of the randomized controlled trial in oncology over three decades

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

The ADVANTAGE seeding trial: a review of internal documents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Results, rhetoric, and randomized trials: the case of donepezil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Pharmaceutical company funding and its consequences: a qualitative systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Influence of drug company authorship and sponsorship on drug trial outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Glucosamine for pain in osteoarthritis: why do trial results differ?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Relationship between drug company funding and outcomes of clinical psychiatric research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Publication bias in the pulmonary/allergy literature: effect of pharmaceutical company sponsorship.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

A meta-analysis comparing trials of antimuscarinic medications funded by industry or not.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Bias from industry trial funding? A framework, a suggested approach, and a negative result

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Extent and impact of industry sponsorship conflicts of interest in dermatology research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Industry sponsorship and authorship of clinical trials over 20 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Quantitative analysis of sponsorship bias in economic studies of antidepressants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Equipoise and the ethics of clinical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

Validation of an index of the quality of review articles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

22 August 2017

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

6 September 2017

The association between funding by commercial interests and study outcome in randomized controlled drug trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

14 September 2017

Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

28 September 2017

Influences on the quality of published drug studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

28 September 2017

Adverse effects of inhaled corticosteroids in funded and nonfunded studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

1 September 2018

Haematological anticancer drugs in Europe: any added value at the time of approval?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

1 September 2018

Association of funding and findings of pharmaceutical research at a meeting of a medical professional society.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

1 September 2018

Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2868984

1 September 2018

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20467553

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stopping a trial early in oncology: for patients or for industry?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20467553

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20467553

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The uncertainty principle and industry-sponsored research

1 reference

https://pubmed.ncbi.nlm.nih.gov/20467553

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3238/ARZTEBL.2010.0279

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

release_7hxntxgl7rhllfri2a477o7z3q

1 reference

https://api.fatcat.wiki/v0/release/7hxntxgl7rhllfri2a477o7z3q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37751910&oldid=2175874326"